Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drug-Drug Interaction Database Will Be Functional By 2000, Plan Says

This article was originally published in The Tan Sheet

Executive Summary

FDA's drug-drug interaction scientific database will be functional two years ahead of schedule in the Center for Drug Evaluation & Research, according to FDA's revised Prescription Drug User Fee Act information management plan issued Aug. 27.

You may also be interested in...

User Fee Workload Decline Leads To Staff Decreases In Regulatory Affairs

FDA's Office of Regulatory Affairs will reduce its Prescription Drug User Fee Act II-funded staff by 40 full-time equivalents for each of the remaining two years of the act's authorization period. The plan calls for 10 fewer FTEs in fiscal 1999, and for 40 fewer FTEs in each subsequent year through 2002.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts